Establishment Labs Posts 45% Revenue Growth to $64.6M, Narrows Loss to $0.09 EPS
Establishment Labs generated $64.6 million in fourth-quarter revenue, a 45.2% year-over-year increase, and narrowed its loss to $0.09 per share versus an expected $0.22 loss. The company ended 2025 with $211.1 million in revenue and maintained a 3.04 current ratio and 0.12 debt-to-equity ratio.
1. Fourth-Quarter Financial Results
Establishment Labs generated $64.6 million in fourth-quarter revenue, up 45.2% year-over-year, and reported a loss of $0.09 per share compared with an expected loss of $0.22. This marks a substantial improvement from a $0.98 per-share loss in the same period last year.
2. Full-Year 2025 Revenue
For the full year, the company achieved $211.1 million in revenue, reflecting continued expansion in its breast aesthetics and reconstruction business and outperforming prior annual results.
3. Strong Liquidity Position
A current ratio of 3.04 demonstrates the company’s ability to cover short-term obligations, supporting ongoing operational and strategic initiatives.
4. Conservative Capital Structure and Valuation
With a debt-to-equity ratio of 0.12, the company maintains low leverage, while a price-to-sales ratio of 10.15 and an EV/S ratio of 9.80 indicate investor confidence despite a negative P/E of -42.77.